NCT00818207 (ACCESSATION) is a Phase 4 clinical trial of Full Smoking Cessation Treatment Coverage (100%) in Smoking Cessation, sponsored by Pfizer.

Who is sponsoring NCT00818207?

NCT00818207 is sponsored by Pfizer.

What drugs are being tested in NCT00818207?

Interventions in NCT00818207: Full Smoking Cessation Treatment Coverage (100%), No Smoking Cessation Treatment Coverage (0%).

What condition does NCT00818207 study?

NCT00818207 studies Smoking Cessation, Insurance Coverage.

Is NCT00818207 still recruiting?

NCT00818207 is currently completed. Last updated 29 February 2012.

Are results published for NCT00818207?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2012-02-29 · How we verify

NCT00818207: ACCESSATION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pragmatic, Randomized, Controlled Study Evaluating The Impact Of Access To Smoking Cessation Treatment Reimbursement On The Proportion Of Successful Quitters In A Canadian Population Of Smokers Motivated To Quit

Completed Phase 4 Results posted Last updated 29 February 2012

What this trial tests

Phase 4 trial testing Full Smoking Cessation Treatment Coverage (100%) in Smoking Cessation in 1,380 participants. Completed in 1 September 2010.

Timeline

1 March 2009

Primary endpoint
1 March 2010

1 September 2010

Quick facts

Lead sponsor	Pfizer
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	1,380
Start date	1 March 2009
Primary completion	1 March 2010
Estimated completion	1 September 2010
Sites	56 locations across Canada

Drugs / interventions tested

Full Smoking Cessation Treatment Coverage (100%)
No Smoking Cessation Treatment Coverage (0%)

Conditions studied

Smoking Cessation — all drugs for Smoking Cessation →
Insurance Coverage — all drugs for Insurance Coverage →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 75, any sex, with Smoking Cessation or Insurance Coverage. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants With 7-Day Point Prevalence (PP) of Abstinence
Time frame: Week 26
Percentage of participants who self-reported tobacco abstinence for the previous 7 days (7-day PP) with a negative response to the following questions: "Have you smoked any cigarettes (even a puff) in the last 7 days?" and "Have you used any nicotine-containing product (such as chew, snuff, pipe, cigar) other than a Nicotine Replacement Therapy (NRT) (smoking cessation treatment \[SCT\]) in the la

Sponsor's own description

This study is based on the hypothesis that access to smoking cessation treatment (SCT) reimbursement may significantly increase the number of successful quitters in a population of smokers motivated to quit by: 1) increasing the use of SCTs in quit attempts, and 2) by improving subject adherence to treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial.
Selby P, Brosky G, Oh PI, Raymond V, et al · · 2012 · cited 22× · PMID 22824225 · DOI 10.1186/1471-2288-12-101
A pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION).
Selby P, Brosky G, Oh P, Raymond V, et al · · 2014 · cited 15× · PMID 24885542 · DOI 10.1186/1471-2458-14-433

Verify or expand the search:

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00818207 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 29 February 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00818207.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing